Tomohiro Kaneta
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Tomohiro Kaneta has a total of 73 co-authors. Here are the top co-authors by number of shared publications:
Shoki Takahashi
Tohoku University
15 shared publicationsHiroshi Fukuda
Tohoku University
14 shared publicationsShogo Yamada
12 shared publicationsTakashi Hakamatsuka
Tohoku University
7 shared publications- Kentaro Takanami
Department of Diagnostic Radiology, Tohoku University Hospital, Sendai, Japan
6 shared publications Akihiro Sato
5 shared publications
Latest Publications
- 10 January 2014
- Published by Springer Nature in Japanese Journal of Radiology
- Vol. 32 (3) , 138-144
Analysis of early phase [11C]BF-227 PET, and its application for anatomical standardization of late-phase images for 3D-SSP analysis
To examine the usefulness of the early phase [11C]BF-227 positron emission tomography (PET) for (1) conferring additional diagnostic value by providing perfusion-like information and (2) obtaining the appropriate anatomical standardization (AS) using three-dimensional stereotactic surface projection (3D-SSP) method.
- 10 January 2014
- Published by Springer Nature in Japanese Journal of Radiology
- Vol. 32 (3) , 138-144
Analysis of early phase [11C]BF-227 PET, and its application for anatomical standardization of late-phase images for 3D-SSP analysis
To examine the usefulness of the early phase [11C]BF-227 positron emission tomography (PET) for (1) conferring additional diagnostic value by providing perfusion-like information and (2) obtaining the appropriate anatomical standardization (AS) using three-dimensional stereotactic surface projection (3D-SSP) method.
- 19 March 2013
- Published by Springer Nature in Annals of Nuclear Medicine
- Vol. 27 (4) , 309-313
A brief review of Japanese guidelines for the clinical use of 18F-FDG-PET/MRI 2012 (Ver 1.0)
This is a brief review of Japanese FDG-PET/MRI guidelines for indications, procedures, cautions for the interpretation of images, and safety management, which were created by a joint task force of the Japanese Radiologic Society, Japanese Society of Nuclear Medicine, and Japanese Society of Magnetic Resonance Imaging. The guidelines aim at the appropriate and effective use of the newly developed PET/MRI modality.
- 19 March 2013
- Published by Springer Nature in Annals of Nuclear Medicine
- Vol. 27 (4) , 309-313
A brief review of Japanese guidelines for the clinical use of 18F-FDG-PET/MRI 2012 (Ver 1.0)
This is a brief review of Japanese FDG-PET/MRI guidelines for indications, procedures, cautions for the interpretation of images, and safety management, which were created by a joint task force of the Japanese Radiologic Society, Japanese Society of Nuclear Medicine, and Japanese Society of Magnetic Resonance Imaging. The guidelines aim at the appropriate and effective use of the newly developed PET/MRI modality.
- 27 July 2011
- Published by Springer Nature in Annals of Nuclear Medicine
- Vol. 25 (10) , 732-739
A modified method of 3D-SSP analysis for amyloid PET imaging using [11C]BF-227
- 27 July 2011
- Published by Springer Nature in Annals of Nuclear Medicine
- Vol. 25 (10) , 732-739
A modified method of 3D-SSP analysis for amyloid PET imaging using [11C]BF-227
- 21 December 2010
- Published by Springer Nature in Annals of Nuclear Medicine
- Vol. 25 (4) , 241-246
Positive correlations between tumor uptake on FDG PET and energy expenditure of patients with esophageal cancer
Cancer patients are prone to clinical malnutrition; moreover, the energy expenditure in patients with certain cancers is higher than that in healthy individuals, rendering their nutritional management a challenging issue. We hypothesized that 2-deoxy-2-[18F]fluoro-d-glucose (FDG) uptake on positron emission tomography (PET) may be related to the energy expenditure and analyzed the FDG uptake and energy expenditure in esophageal cancer patients to clarify this. Esophageal cancer patients [n = 13, 10 males and 3 females, age 66.5 ± 8.9 (51–82) years] were evaluated for FDG uptake using PET. The resting energy expenditure (REE) and basal energy expenditure (BEE) were calculated using indirect calorimetry and the Harris–Benedict formula, respectively. Regression analyses were performed to compare the parameters of imaging and energy expenditure. Positive correlations were found between tumor uptake on FDG PET and the parameters of energy expenditure. Among them, the correlations between SUVmax and the ratio of REE to BEE (REE/BEE, r = 0.59; p = 0.035) and between SUVmax and the difference between REE and BEE (REE − BEE, r = 0.58; p = 0.036) were moderate and statistically significant. Further, the correlation between tumor uptake expressed as a percentage (%TU) and REE/BEE was mild (r = 0.51) but not significant (p = 0.07), while that between %TU and REE–BEE was weak (r = 0.42) and not significant (p = 0.15). Significant positive correlations between SUVmax on FDG PET and energy expenditure were noted in our study; we consider that these results may aid in determining the nutritional management for esophageal cancer patients.
- 21 December 2010
- Published by Springer Nature in Annals of Nuclear Medicine
- Vol. 25 (4) , 241-246
Positive correlations between tumor uptake on FDG PET and energy expenditure of patients with esophageal cancer
Cancer patients are prone to clinical malnutrition; moreover, the energy expenditure in patients with certain cancers is higher than that in healthy individuals, rendering their nutritional management a challenging issue. We hypothesized that 2-deoxy-2-[18F]fluoro-d-glucose (FDG) uptake on positron emission tomography (PET) may be related to the energy expenditure and analyzed the FDG uptake and energy expenditure in esophageal cancer patients to clarify this. Esophageal cancer patients [n = 13, 10 males and 3 females, age 66.5 ± 8.9 (51–82) years] were evaluated for FDG uptake using PET. The resting energy expenditure (REE) and basal energy expenditure (BEE) were calculated using indirect calorimetry and the Harris–Benedict formula, respectively. Regression analyses were performed to compare the parameters of imaging and energy expenditure. Positive correlations were found between tumor uptake on FDG PET and the parameters of energy expenditure. Among them, the correlations between SUVmax and the ratio of REE to BEE (REE/BEE, r = 0.59; p = 0.035) and between SUVmax and the difference between REE and BEE (REE − BEE, r = 0.58; p = 0.036) were moderate and statistically significant. Further, the correlation between tumor uptake expressed as a percentage (%TU) and REE/BEE was mild (r = 0.51) but not significant (p = 0.07), while that between %TU and REE–BEE was weak (r = 0.42) and not significant (p = 0.15). Significant positive correlations between SUVmax on FDG PET and energy expenditure were noted in our study; we consider that these results may aid in determining the nutritional management for esophageal cancer patients.
- Open Access
- 7 April 2010
- Published by Springer Nature in BMC Cancer
- Vol. 10 (1) , 127
Focal dose escalation using FDG-PET-guided intensity-modulated radiation therapy boost for postoperative local recurrent rectal cancer: a planning study with comparison of DVH and NTCP
To evaluate the safety of focal dose escalation to regions with standardized uptake value (SUV) >2.0 using intensity-modulated radiation therapy (IMRT) by comparison of radiotherapy plans using dose-volume histograms (DVHs) and normal tissue complication probability (NTCP) for postoperative local recurrent rectal cancer
- 7 April 2010
- Published by Springer Nature in BMC Cancer
- Vol. 10 (1) , 127
Open AccessFocal dose escalation using FDG-PET-guided intensity-modulated radiation therapy boost for postoperative local recurrent rectal cancer: a planning study with comparison of DVH and NTCP
To evaluate the safety of focal dose escalation to regions with standardized uptake value (SUV) >2.0 using intensity-modulated radiation therapy (IMRT) by comparison of radiotherapy plans using dose-volume histograms (DVHs) and normal tissue complication probability (NTCP) for postoperative local recurrent rectal cancer
- 1 June 2009
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 34 (6) , 395-397
FDG Accumulation in Obturator Herniation of the Bladder Mimicking Metastatic Disease
FDG PET was performed on a 73-year-old woman as a follow-up examination after chemoradiotherapy for esophageal cancer. Increased uptake was noted in the left inguinal region, suggesting a metastatic lymph node. PET/CT revealed that the precise location of the hot spot was in the left obturator foramen. Previous FDG PET had shown the continuity of the bladder uptake to the left obturator foramen, suggesting obturator herniation of the bladder.
- 1 June 2009
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 34 (6) , 395-397
FDG Accumulation in Obturator Herniation of the Bladder Mimicking Metastatic Disease
FDG PET was performed on a 73-year-old woman as a follow-up examination after chemoradiotherapy for esophageal cancer. Increased uptake was noted in the left inguinal region, suggesting a metastatic lymph node. PET/CT revealed that the precise location of the hot spot was in the left obturator foramen. Previous FDG PET had shown the continuity of the bladder uptake to the left obturator foramen, suggesting obturator herniation of the bladder.
- 30 May 2008
- Vol. 55 (81) , 46-9
Increase of serum CA19-9 level without an evident lesion on conventional imaging is insufficient for justification of 18FDG-PET examination.
The serum tumor marker carbohydrate associated antigen 19-9 (CA19-9) has been used for screening for cancer, because its increase has been associated with many cancers. We aimed to evaluate the clinical value of positron emission tomography using F-18 fluorodeoxyglucose (18FDG-PET) that was prompted by increases of serum CA19-9 without findings on conventional imaging. Twenty-two patients were retrospectively selected. Eleven were without a history of cancer and eleven had a history of cancer and were treated with curative intent. All 18FDG-PET findings were compared with the findings of histopathology by surgery or biopsy, or clinical follow-up for at least 1 year. We found only two true positive cases, and eleven cases without a cancer history included 10 true negatives and one false positive. Increases in serum CA19-9 are caused by many benign conditions. Increases of CA19-9 without findings on conventional imaging do not justify 18FDG-PET examination, particularly in patients without a cancer history.
- 30 May 2008
- Vol. 55 (81) , 46-9
Increase of serum CA19-9 level without an evident lesion on conventional imaging is insufficient for justification of 18FDG-PET examination.
The serum tumor marker carbohydrate associated antigen 19-9 (CA19-9) has been used for screening for cancer, because its increase has been associated with many cancers. We aimed to evaluate the clinical value of positron emission tomography using F-18 fluorodeoxyglucose (18FDG-PET) that was prompted by increases of serum CA19-9 without findings on conventional imaging. Twenty-two patients were retrospectively selected. Eleven were without a history of cancer and eleven had a history of cancer and were treated with curative intent. All 18FDG-PET findings were compared with the findings of histopathology by surgery or biopsy, or clinical follow-up for at least 1 year. We found only two true positive cases, and eleven cases without a cancer history included 10 true negatives and one false positive. Increases in serum CA19-9 are caused by many benign conditions. Increases of CA19-9 without findings on conventional imaging do not justify 18FDG-PET examination, particularly in patients without a cancer history.
- 25 December 2007
- Published by Springer Nature in Annals of Nuclear Medicine
- Vol. 21 (10) , 597-601
Evaluation of portosystemic shunt caused by patent ductus venosus through sequential whole-body scanning using per-sigmoid colon 123I-IMP scintigraphy
The correct estimation of the portosystemic shunt (PSS) ratio prior to surgery for patent ductus venosus is important. Until now, formulas using the lung and liver uptake for per-rectal portal scintigraphy using 123I-iodoamphetamine (IMP) have been mainly used for calculating the PSS ratio. However, these methods did not take radioactivity in the brain or changes in organ radioactivity over time into consideration. Here, we performed sequential whole-body scanning by per-sigmoid colon 123I-IMP scintigraphy, and evaluated the changes in radioactivity in the liver, lungs, and brain over time. The patient was 7-year-old boy with a patent ductus venosus. A 10 Fr. catheter was inserted into the sigmoid colon under fluoroscopic guidance, through which about 55.5 MBq of 123I-IMP was administered. Following the administration, the patient was placed in the supine position and sequential whole-body scanning (from head to thigh) was performed for up to about 80 min. Four regions of interest (ROIs) were placed on the whole brain, lungs, liver, and mediastinum. The PSS ratios were calculated using both the traditional formula (PSS index: brain uptake is not considered) and our original formula (new index: brain uptake is considered). Prior to surgery, the radioactivity could be seen clearly in the brain and lungs just following the injection. The liver uptake was faint on the first and second scans (15 min/scan), and increased gradually over time. In contrast, almost no radioactivity was detected in the brain or lungs following surgery. The liver uptake could be seen clearly just following the injection. The new index was significantly higher than the PSS index. Both the new index and the PSS index showed changes over time especially prior to surgery. Distinct brain radioactivity was observed early following administration in a patient with PSS. The calculation of the PSS fraction should be performed taking the brain radioactivity into consideration. The timing of the scan should be fixed, but 30 min following administration may be too early to begin scanning.
- 25 December 2007
- Published by Springer Nature in Annals of Nuclear Medicine
- Vol. 21 (10) , 597-601
Evaluation of portosystemic shunt caused by patent ductus venosus through sequential whole-body scanning using per-sigmoid colon 123I-IMP scintigraphy
The correct estimation of the portosystemic shunt (PSS) ratio prior to surgery for patent ductus venosus is important. Until now, formulas using the lung and liver uptake for per-rectal portal scintigraphy using 123I-iodoamphetamine (IMP) have been mainly used for calculating the PSS ratio. However, these methods did not take radioactivity in the brain or changes in organ radioactivity over time into consideration. Here, we performed sequential whole-body scanning by per-sigmoid colon 123I-IMP scintigraphy, and evaluated the changes in radioactivity in the liver, lungs, and brain over time. The patient was 7-year-old boy with a patent ductus venosus. A 10 Fr. catheter was inserted into the sigmoid colon under fluoroscopic guidance, through which about 55.5 MBq of 123I-IMP was administered. Following the administration, the patient was placed in the supine position and sequential whole-body scanning (from head to thigh) was performed for up to about 80 min. Four regions of interest (ROIs) were placed on the whole brain, lungs, liver, and mediastinum. The PSS ratios were calculated using both the traditional formula (PSS index: brain uptake is not considered) and our original formula (new index: brain uptake is considered). Prior to surgery, the radioactivity could be seen clearly in the brain and lungs just following the injection. The liver uptake was faint on the first and second scans (15 min/scan), and increased gradually over time. In contrast, almost no radioactivity was detected in the brain or lungs following surgery. The liver uptake could be seen clearly just following the injection. The new index was significantly higher than the PSS index. Both the new index and the PSS index showed changes over time especially prior to surgery. Distinct brain radioactivity was observed early following administration in a patient with PSS. The calculation of the PSS fraction should be performed taking the brain radioactivity into consideration. The timing of the scan should be fixed, but 30 min following administration may be too early to begin scanning.
- 1 June 2007
- Published by Wolters Kluwer Health in Nuclear Medicine Communications
- Vol. 28 (6) , 495-499
High-density materials do not always induce artifacts on PET/CT: What is responsible for the difference?
PET/CT often show increased uptake at sites of high-density materials. However, some materials seldom demonstrate increased uptake on PET/CT, such as the materials used in hip prostheses. We hypothesized that the motion of materials may be crucial for such artifacts. Here, we present representative cases, and validate our hypothesis based on the results of phantom studies. A standard cylinder, 20 cm in diameter, was filled with approximately 37 MBq of 18F-based activity, and a pacemaker was attached to the side of the cylinder. This phantom was placed on the bed with the pacemaker side facing the scanner. PET scans were performed using a Biograph LSO DUO. CT scans were performed first for transmission scans, followed by acquisition of emission scans. The phantom was first scanned (protocol 1). The phantom was then moved about 2 cm closer to the distal edge of the bed just after transmission CT scan, and the emission scan was performed (protocol 2). Homogenous uptake was seen in the cylinder in protocol 1, and there was no visible uptake at the site of the pacemaker. In contrast, a clear hotspot was seen at the site of the pacemaker in protocol 2. The uptake in the cylinder was inhomogeneous; that on the pacemaker side of the cylinder was low, while that on the opposite side was high. High-density materials do not show false increased uptake without motion on PET/CT. Motion of these materials surrounded by radioactive organs may play an important role in inducing false increased uptake on PET/CT.
- 1 June 2007
- Published by Wolters Kluwer Health in Nuclear Medicine Communications
- Vol. 28 (6) , 495-499
High-density materials do not always induce artifacts on PET/CT: What is responsible for the difference?
PET/CT often show increased uptake at sites of high-density materials. However, some materials seldom demonstrate increased uptake on PET/CT, such as the materials used in hip prostheses. We hypothesized that the motion of materials may be crucial for such artifacts. Here, we present representative cases, and validate our hypothesis based on the results of phantom studies. A standard cylinder, 20 cm in diameter, was filled with approximately 37 MBq of 18F-based activity, and a pacemaker was attached to the side of the cylinder. This phantom was placed on the bed with the pacemaker side facing the scanner. PET scans were performed using a Biograph LSO DUO. CT scans were performed first for transmission scans, followed by acquisition of emission scans. The phantom was first scanned (protocol 1). The phantom was then moved about 2 cm closer to the distal edge of the bed just after transmission CT scan, and the emission scan was performed (protocol 2). Homogenous uptake was seen in the cylinder in protocol 1, and there was no visible uptake at the site of the pacemaker. In contrast, a clear hotspot was seen at the site of the pacemaker in protocol 2. The uptake in the cylinder was inhomogeneous; that on the pacemaker side of the cylinder was low, while that on the opposite side was high. High-density materials do not show false increased uptake without motion on PET/CT. Motion of these materials surrounded by radioactive organs may play an important role in inducing false increased uptake on PET/CT.
- 1 February 2007
- Published by Springer Nature in Annals of Nuclear Medicine
- Vol. 21 (2) , 101-107
Initial evaluation of dynamic human imaging using 18F-FRP170 as a new PET tracer for imaging hypoxia.
- 1 February 2007
- Published by Springer Nature in Annals of Nuclear Medicine
- Vol. 21 (2) , 101-107
Initial evaluation of dynamic human imaging using 18F-FRP170 as a new PET tracer for imaging hypoxia.